AbbVie gets option to arGEN-X's immuno-oncology program; option exercised
ArGEN-X NV is partnering its preclinical GARP inhibitor ARGX115 with AbbVie Inc.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.